ABSTRACT
The antiphospholipid syndrome (APS) is characterized by clinical manifestations such
as venous and arterial thrombosis, thrombocytopenia and/or recurrent pregnancy loss,
as well as the persistent presence of laboratory markers of antiphospholipid (aPL)
antibodies detected in laboratory assays. Though it is generally accepted that aPL
antibodies, such as anticardiolipin (aCL), anti–β2 glycoprotein I (anti-β2GPI), and
lupus anticoagulants (LA) contribute to the pathogenesis of APS, precise mechanism(s)
are yet to be fully described. It is probable that aPL antibodies bind to a range
of cellular targets (e.g., platelets, endothelial cells, and monocytes), leading to
thrombosis and obstetric complications. There is now increasing evidence that alterations
to the tissue factor (TF) pathway of blood coagulation contribute toward hypercoagulability
in patients with aPL antibodies. This article reviews current evidence that suggests
changes and/or interference to the major pathway of blood coagulation may represent
a novel mechanism that contributes to the development of APS.
KEYWORDS
Tissue factor - antiphospholipid syndrome - antiphospholipid antibodies - tissue factor
pathway inhibitor - thrombosis
REFERENCES
- 1
Miyakis S, Lockshin M D, Atsumi T et al..
International consensus statement on an update of the classification criteria for
definite antiphospholipid syndrome (APS).
J Thromb Haemost.
2006;
4
295-306
- 2
Malia R G, Kitchen S, Greaves M et al..
Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies.
Br J Haematol.
1990;
76
101-107
- 3
Oosting J D, Derksen R H, Bobbink I W et al..
Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin,
protein C, or protein S: an explanation for their pathogenic mechanism?.
Blood.
1993;
81
2618-2625
- 4
Amengual O, Atsumi T, Khamashta M A et al..
The role of the tissue factor pathway in the hypercoagulable state in patients with
the antiphospholipid syndrome.
Thromb Haemost.
1998;
79
276-281
- 5
Kornberg A, Blank M, Kaufman S et al..
Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies.
J Immunol.
1994;
153
1328-1332
- 6
Escolar G, Font J, Reverter J C et al..
Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies
promotes platelet aggregation. Studies in a perfusion system.
Arterioscler Thromb.
1992;
12
196-200
- 7
Pierangeli S S, Chen P P, Raschi E et al..
Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.
Semin Thromb Hemost.
2008;
34
236-250
- 8
Hoffman M, Monroe III D M.
A cell-based model of hemostasis.
Thromb Haemost.
2001;
85
958-965
- 9
Mackman N, Tilley R E, Key N S.
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis.
Arterioscler Thromb Vasc Biol.
2007;
27
1687-1693
- 10
Mallat Z, Benamer H, Hugel B et al..
Elevated levels of shed membrane microparticles with procoagulant potential in the
peripheral circulating blood of patients with acute coronary syndromes.
Circulation.
2000;
101
841-843
- 11
Ederhy S, Di Angelantonio E, Mallat Z et al..
Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation.
Am J Cardiol.
2007;
100
989-994
- 12
Tesselaar M E, Romijn F P, Van Der Linden I K et al..
Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.
J Thromb Haemost.
2007;
5
520-527
- 13
Rauch U, Antoniak S.
Tissue factor-positive microparticles in blood associated with coagulopathy in cancer.
Thromb Haemost.
2007;
97
9-10
- 14
Werling R W, Zacharski L R, Kisiel W et al..
Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.
Thromb Haemost.
1993;
69
366-369
- 15
Adams M J, Oostryck R.
A comparative study of functional assays for tissue factor pathway inhibitor using
normal plasma and clinical samples.
Blood Coagul Fibrinolysis.
2000;
11
327-333
- 16
Bognacki J, Hammelburger J.
Functional and immunologic methods for the measurement of human tissue factor pathway
inhibitor.
Blood Coagul Fibrinolysis.
1995;
6(Suppl 1)
S65-S72
- 17
Jeske W, Hoppensteadt D, Fareed J et al..
Measurement of functional and immunologic levels of tissue factor pathway inhibitor.
Some methodologic considerations.
Blood Coagul Fibrinolysis.
1995;
6(Suppl 1)
S73-S80
- 18
Rustin M HA, Bull H A, Machin S J et al..
Effects of the lupus anticoagulant in patients with systemic lupus erythematosus in
endothelial cell prostacyclin release and procoagulant activity.
J Invest Dermatol.
1988;
90
744-748
- 19
Hasselaar P, Derksen R H, Oosting J D et al..
Synergistic effect of low doses of tumour necrosis factor and sera from patients with
systemic lupus erythematosus on the expression of procoagulant activity by cultured
endothelial cells.
Thromb Haemost.
1989;
62
654-660
- 20
Tannenbaum S H, Finko R, Cines D B.
Antibody and immune complexes induce tissue factor production by human endothelial
cells.
J Immunol.
1986;
137
1532-1537
- 21
Ferro D, Saliola M, Meroni P L et al..
Enhanced monocyte expression of tissue factor by oxidative stress in patients with
antiphospholipid antibodies: effect of antioxidant treatment.
J Thromb Haemost.
2003;
1
523-531
- 22
Reverter J C, Tassies D, Font J et al..
Effects of human monoclonal anticardiolipin antibodies on platelet function and on
tissue factor expression on monocytes.
Arthritis Rheum.
1998;
41
1420-1427
- 23
Jacobsen E M, Sandset P M, Wisloff F.
Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?.
Thromb Res.
1999;
94
213-220
- 24
Morel O, Jesel L, Freyssinet J M et al..
Elevated levels of procoagulant microparticles in a patient with myocardial infarction,
antiphospholipid antibodies and multifocal cardiac thrombosis.
Thromb J.
2005;
3
15
- 25
Dignat-George F, Camoin-Jau L, Sabatier F et al..
Endothelial microparticles: a potential contribution to the thrombotic complications
of the antiphospholipid syndrome.
Thromb Haemost.
2004;
91
667-673
- 26
Enjeti A K, Lincz L F, Seldon M.
Detection and measurement of microparticles: an evolving research tool for vascular
biology.
Semin Thromb Hemost.
2007;
33
771-779
- 27
Adams M, Breckler L, Stevens P et al..
Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome
is associated with increased thrombin generation.
Haematologica.
2004;
89
985-990
- 28
Adams M J, Donohoe S, Mackie I J et al..
Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid
syndrome.
Br J Haematol.
2001;
114
375-379
- 29
Adams M J, Dunstan R A, Oostryck R.
Interference by lupus anticoagulant in a functional assay for tissue factor pathway
inhibitor.
Thromb Res.
1995;
80
435-440
- 30
Adams M J, Oostryck R.
Further investigations of lupus anticoagulant interference in a functional assay for
tissue factor pathway inhibitor.
Thromb Res.
1997;
87
245-249
- 31
Lean S Y, Ellery P, Ivey L et al..
The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG
on thrombin generation.
Haematologica.
2006;
91
1360-1366
- 32
Forastiero R R, Martinuzzo M E, Broze G J.
High titers of autoantibodies to tissue factor pathway inhibitor are associated with
the antiphospholipid syndrome.
J Thromb Haemost.
2003;
1
718-724
- 33
Salemink I, Blezer R, Willems G M et al..
Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress
the inhibitory activity of tissue factor pathway inhibitor.
Thromb Haemost.
2000;
84
653-656
- 34
Liestol S, Sandset P M, Jacobsen E M et al..
Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas
from patients with lupus anticoagulants.
Br J Haematol.
2007;
136
131-137
- 35
Sheng Y, Hanly J G, Reddel S W et al..
Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin
generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus
antibodies binding beta(2)-glycoprotein I and prothrombin.
Clin Exp Immunol.
2001;
124
502-508
Murray AdamsPh.D. M.A.I.M.S.
School of Human Life Sciences, University of Tasmania
Tasmania, Australia
eMail: Murray.Adams@utas.edu.au
